

---

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 14, 2011**

**LANTHEUS MEDICAL IMAGING, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**333-169785**

(Commission File Number)

**51-0396366**

(IRS Employer Identification No.)

**331 Treble Cove Road, North Billerica, MA 01862**

(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: **(978) 671-8001**

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 
-

**Item 8.01 Other Events**

*Appointment of Chief Financial Officer*

On January 14, 2011, Robert Gaffey was appointed to the position of Chief Financial Officer of Lantheus Medical Imaging, Inc. (the “Company”). Mr. Gaffey, age 63, previously served as Vice President, Finance and Information Technology, and Treasurer, a position he held since January 2008. In his expanded role as Chief Financial Officer, Mr. Gaffey remains the Company’s principal financial officer and will continue to serve as Treasurer. Mr. Gaffey has held multiple positions with the Company since 1987, including Vice President Finance, Operations and General Manager Billerica Site, and Vice President Finance and Operations. Mr. Gaffey began his career with E.I. DuPont de Nemours. Mr. Gaffey holds a Bachelor of Science in Accounting from Bentley College and a Master of Business Administration from Widener University.

A copy of the Company’s press release, dated January 18, 2011, announcing the promotion of Robert Gaffey to Chief Financial Officer, is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit Number</u>	<u>Description of Exhibits</u>
99.1	Press Release, dated January 18, 2011, announcing the promotion of Robert Gaffey to Chief Financial Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LANTHEUS MEDICAL IMAGING, INC.

By: /s/ Michael P. Duffy  
Name: Michael P. Duffy  
Title: Vice President and General Counsel

Date: January 18, 2011

**EXHIBIT LIST**

**Exhibit  
Number**

**Description of Exhibits**

99.1

Press Release, dated January 18, 2011, announcing the promotion of Robert Gaffey to Chief Financial Officer



331 Treble Cove Road  
North Billerica, MA 01862

800.362.2668  
[www.lantheus.com](http://www.lantheus.com)

**Contacts:**

Linda Lennox  
Lantheus Medical Imaging  
Office: 978-671-8854  
Cell: 978-995-5698

Michele Rozen  
Pure Communications  
Office: 617-730-8284  
Cell: 617-953-2214

**LANTHEUS MEDICAL IMAGING ANNOUNCES PROMOTION OF ROBERT GAFFEY TO CHIEF FINANCIAL OFFICER**

**No. BILLERICA, Mass. (January 18, 2011)** — Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the promotion of Robert Gaffey to Chief Financial Officer. He was most recently Vice President, Finance and Information Technology. In this expanded role, Mr. Gaffey will add the leadership for investor relations and strategic corporate communications to his current responsibilities of directing the Company's global financial strategy. Mr. Gaffey will continue to report to Lantheus President and Chief Executive Officer, Don Kiepert.

"Bob has been a tremendous asset to the Company, having served in multiple leadership roles since the Company's early days," said Mr. Kiepert. "This promotion reflects his many contributions to the Company and the instrumental role he played in leading the Company into the public domain through our recent bond offering. As Chief Financial Officer, Bob's financial expertise will continue to be of significant value as we execute our corporate strategy and grow the Company."

Mr. Gaffey has served in several key leadership positions at the Company for more than 35 years. Starting his career when the Company was part of E.I. DuPont de Nemours, he helped lead the Company through its transition to Bristol-Myers Squibb Medical Imaging and the sale to a private equity investment firm, which re-launched the Company as Lantheus Medical Imaging. Mr. Gaffey earned a B.S. from Bentley College and an M.B.A. from Widener University.

**About Lantheus Medical Imaging, Inc.**

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medicine for more than 50 years, is dedicated to creating and providing pioneering medical imaging solutions to improve

---

the treatment of human disease. The Company's proven success in discovering, developing and marketing innovative medical imaging agents provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, ABLAVAR® (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechnoLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has more than 650 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit [www.lantheus.com](http://www.lantheus.com).

**Safe Harbor for Forward-Looking and Cautionary Statements**

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that may be described from time to time in the Company's filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

###

---